Photo from wikipedia
The addition of chemotherapy to a programmed death 1/programmed death ligand 1 (PD‐L1) inhibitor is a more effective option as a first‐line treatment for advanced non–small cell lung cancer (NSCLC).… Click to show full abstract
The addition of chemotherapy to a programmed death 1/programmed death ligand 1 (PD‐L1) inhibitor is a more effective option as a first‐line treatment for advanced non–small cell lung cancer (NSCLC). It might also inhibit an overactive immune response and thereby reduce immune‐related adverse events (irAEs). This meta‐analysis assessed the rate of irAEs with a PD‐(L)1 inhibitor plus chemotherapy (I+C) versus a PD‐(L)1 inhibitor alone (I) and evaluated the indirect relative risk (RR) of I+C versus I.
Keywords:
chemotherapy;
inhibitor;
first line;
versus;
line treatment;
cancer
Journal Title: Cancer
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!